Nimrata Hunt - Aug 11, 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Executive Vice President
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt
Stock symbol
IDXX
Transactions as of
Aug 11, 2025
Transactions value $
-$488,496
Form type
4
Date filed
8/13/2025, 05:17 PM
Previous filing
Aug 8, 2025
Next filing
Nov 10, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hunt Nimrata Executive Vice President ONE IDEXX DRIVE, WESTBROOK /s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt 2025-08-13 0001800619

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Sale -$788K -1.2K -6.66% $656.53 16.8K Aug 11, 2025 Direct
transaction IDXX Common Stock Options Exercise $99.8K +560 +3.33% $178.26 17.4K Aug 12, 2025 Direct
transaction IDXX Common Stock Options Exercise $100K +483 +2.78% $206.94 17.8K Aug 12, 2025 Direct
transaction IDXX Common Stock Options Exercise $99.6K +183 +1.03% $544.08 18K Aug 12, 2025 Direct
holding IDXX Common Stock 160 Aug 11, 2025 jointly with spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Incentive Stock Option (right-to-buy) Options Exercise $0 -560 -100% $0.00 0 Aug 12, 2025 Common Stock 560 $178.26 Direct F1
transaction IDXX Incentive Stock Option (right-to-buy) Options Exercise $0 -483 -100% $0.00 0 Aug 12, 2025 Common Stock 483 $206.94 Direct F2
transaction IDXX Incentive Stock Option (right-to-buy) Options Exercise $0 -183 -100% $0.00 0 Aug 12, 2025 Common Stock 183 $544.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2023.
F2 Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2024.
F3 Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.